ChromaVision Introduces Automated Test for Cancer

SAN JUAN CAPISTRANO, Calif., June 26 -- ChromaVision Medical Systems Inc. has unveiled a new immunohistochemical (IHC) test to aid in the detection of micrometastases in patients' tissue that have spread from the primary tumor. The new test will be used for lymph node evaluation in breast cancer.
ChromaVision's Automated Cellular Imaging System combines its color-based imaging technology with automated microscopy to provide sensitivity, accuracy and reproducibility to the evaluation of cell-based diseases such as cancer and infectious disease. ChromaVision sells its products to physicians and researchers in university medical centers and commercial laboratories worldwide.